Nykode Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Nykode Therapeutics has a total shareholder equity of $171.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $208.2M and $36.9M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$162.60m |
| Equity | US$171.26m |
| Total liabilities | US$36.93m |
| Total assets | US$208.19m |
Recent financial health updates
We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20
Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Recent updates
Earnings Update: Nykode Therapeutics AS (OB:NYKD) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts
Mar 02Risks To Shareholder Returns Are Elevated At These Prices For Nykode Therapeutics AS (OB:NYKD)
Jan 22We Think Nykode Therapeutics (OB:NYKD) Can Easily Afford To Drive Business Growth
Aug 20Nykode Therapeutics (OB:NYKD) Is In A Strong Position To Grow Its Business
Apr 06Could The Vaccibody AS (OB:VACC) Ownership Structure Tell Us Something Useful?
Jan 25
Financial Position Analysis
Short Term Liabilities: NYKD's short term assets ($165.7M) exceed its short term liabilities ($20.6M).
Long Term Liabilities: NYKD's short term assets ($165.7M) exceed its long term liabilities ($16.3M).
Debt to Equity History and Analysis
Debt Level: NYKD is debt free.
Reducing Debt: NYKD has not had any debt for past 5 years.
Debt Coverage: NYKD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NYKD has no debt, therefore coverage of interest payments is not a concern.